ArticleMicroorganisms2024
Exploring the Effects of Imidacloprid on Liver Health and the Microbiome in Rats: A Comprehensive Study.
Article in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Imidacloprid induces hepatorenal toxicity in male albino rats via oxidative, immune inflammatory, and proliferative effects: a 90-day study.Scientific reports · 2026Article
- Article
- Pesticides Drive Liver Diseases Through Non-Apoptotic Regulated Cell Death Pathways.Diseases (Basel, Switzerland) · 2026Review
- Nutritional nanotherapy with quercetin-loaded chitosan nanoparticles ameliorates imidacloprid-induced liver toxicity through antioxidant, anti-Inflammatory, and genoprotective mechanisms.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The Impact of Human Immunodeficiency Virus Co‑Infection on the Pathogen Spectrum and Outcomes of Severe Community‑Acquired Pneumonia: Insights from Metagenomic Next‑Generation Sequencing.Infection and drug resistance · 2026Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current study investigates the systemic effects of imidacloprid, one of the most widely used neonicotinoid insecticides, on the liver and gut microbiome of rats in detail. With consideration of recent discussions on the potential harmfulness of imidacloprid to environmental and human health, the aim was to investigate the influence of this compound in the framework of controlled exposure at different dosages, namely, IMI-5, IMI-10, and IMI-30. Histopathological examination showed that liver morphology changed significantly with the dose, including in terms of cellular disorganization and signs of stress, with an alteration in the hepatic architecture. Morphological changes were related to disturbances in the activity of liver enzymes, reflecting deteriorating liver function with increased imidacloprid exposure. In parallel with this, a deep analysis of the gut microbiome revealed dramatic changes in microbial diversity and composition. Alpha diversity, represented by the Chao1 and Shannon indices, was significantly reduced with an increased dosage of imidacloprid. Subsequent beta diversity analysis, as visualized by principal component analysis, showed distinct clustering among the microbial communities, separated well between control and imidacloprid-treated groups, especially at higher dosages. Taxonomic analysis revealed an increase in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.